Exchange: NASDAQ·Updated 03:59 PM EST

BTAI News

News
all
press releases
BioXcel Therapeutics Agrees To Teva Asset Sale
(RTTNews) - BioXcel Therapeutics Inc. (BTAI) on Friday entered into an agreement to sell substantially all of its assets to Teva Pharmaceuticals International GmbH (TEVA.TA) and filed for voluntary Chapter 11 bankruptcy...
Nasdaq News: Markets
BioXcel Therapeutics Agrees To Teva Asset Sale
(RTTNews) - BioXcel Therapeutics Inc. (BTAI) on Friday entered into an agreement to sell substantially all of its assets to Teva Pharmaceuticals International GmbH (TEVA.TA) and filed for voluntary Chapter 11 bankruptcy...
Nasdaq News: Markets
More News
BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of +3.92% and -46.47%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
BioMarin (BMRN) delivered earnings and revenue surprises of +25.00% and +7.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
BioXcel Therapeutics (BTAI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of +8.48% and -28.97%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
CorMedix (CRMD) delivered earnings and revenue surprises of +24.64% and +16.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Verastem (VSTM) delivered earnings and revenue surprises of 0.00% and -16.09%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
BioXcel Therapeutics (BTAI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, April 9, 2026 Shareholders are encouraged to contact the firm to discuss their rights and options at no...
PR Newswire
BioXcel Therapeutics shares fall after a rally as BXCL501 Phase 2 data show promise for treating opioid withdrawal symptoms.read more...
Benzinga

Advertisement|Remove ads.